Payment overview · 2025
General Payments
$234.51
9 reported records · 5 companies
Healthcare provider profile · identity verified
Paul Leitner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1912093865
Verified facts
What the public records show
CMS Open Payments records show Paul Leitner, MD received $234.51 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.29 | 37.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.98 | 21.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.25 | 17.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.20 | 13.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.79 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.51 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.29 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 242 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 40 |
| Lisinopril | Lisinopril | 174 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 31 |
| Eliquis | Apixaban | 138 | 17 |
| Gabapentin | Gabapentin | 135 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 20 |
| Prednisone | Prednisone | 118 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 22 |
| Furosemide | Furosemide | 106 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 19 |
| Januvia | Sitagliptin Phosphate | 80 | 13 |
| Potassium Chloride | Potassium Chloride | 78 | 17 |
| Diazepam | Diazepam | 76 | 13 |
| Metformin Hcl | Metformin Hcl | 74 | 17 |
| Donepezil Hcl | Donepezil Hcl | 68 | 15 |
| Carvedilol | Carvedilol | 66 | 12 |
| Losartan Potassium | Losartan Potassium | 66 | 22 |
| Omeprazole | Omeprazole | 66 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 16 |
| Alprazolam | Alprazolam | 58 | suppressed |
| Famotidine | Famotidine | 53 | 13 |
| Cephalexin | Cephalexin | 50 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Sertraline Hcl | Sertraline Hcl | 45 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 15 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Lactulose | Lactulose | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 20 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Naproxen | Naproxen | 38 | 13 |
| Simvastatin | Simvastatin | 38 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 16 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.51 · 9 records | GlaxoSmithKline, LLC. | AIRSUPRA, Cologuard Collection Kit, Leqembi, REPATHA, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error